Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022

Author:

Singh Ankit Kumar1,Sonawane Pankaj1,Kumar Adarsh1,Singh Harshwardhan1,Naumovich Vladislav2,Pathak Prateek2,Grishina Maria2ORCID,Khalilullah Habibullah3,Jaremko Mariusz4,Emwas Abdul-Hamid5,Verma Amita6ORCID,Kumar Pradeep1ORCID

Affiliation:

1. Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 151401, India

2. Laboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, Chelyabinsk 454008, Russia

3. Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unayzah 51911, Saudi Arabia

4. Smart-Health Initiative and Red Sea Research Center, Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia

5. Core Laboratories, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia

6. Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India

Funder

King Abdullah University of Science and Technology

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3